Early prophylaxis reduces bone loss in haemophilia, while delayed or absent treatment increases osteoporosis risk.

Pivotal Phase 3 data from RAPIDe-3 of deucrictibant for the on-demand treatment of HAE attacks to be presented for the first ...

CorMedix (NASDAQ:CRMD) used its 2026 Analyst and Investor Day to outline its shift from a single-product renal-focused ...

If approved, marstacimab would be the first non-factor prophylactic treatment indicated for pediatric patients aged 6 to 11 years with hemophilia B.

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority ...

Doctor Phi Phi treats monkey bites, animal bites with rabies vaccination. WHO-standard PEP, 2 locations, 4.9★ rated.

Discover effective strategies for monitoring and managing CRS toxicity and ICANS, enhancing patient care and reducing burdens ...

Pfizer gets FDA priority review for Hympavzi to treat children 6-11 with hemophilia A or B, expanding current U.S. approvals.

Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no ...

Indiana’s laws punish people living with HIV for actions that do not transmit the virus.

Compressed tablets of tivoxavir marboxil predicted to provide 28-day protection from influenza against wide range of seasonal and pandemic-potential variants ...

Individualized treatment, rather than presumed superiority, should shape decisions ...